Magnetic particles and targeting systems for magnetic cell delivery
Genes & Cells · 13.03.2026 · 21 (1) · 62-76
DOI: 10.17816/gc690530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes & Cells, online erschienen am 13.03.2026. Verfasst von Viktor V. Turchyn und 6 weiteren Autor:innen. Die Arbeit nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: The number of studies investigating physical methods of cell targeting is steadily growing. Within the field of magnetic cell targeting, two main approaches have recently emerged: the use of microscale structures as magnetic carriers, e.g, porous spheroids, helices, and microrobots, that transport cells, and the use of nano- or microscale magnetic particles that directly label cells. AIM: The study aimed to review experimental studies on the use of magnetic particles for targeted delivery of mammalian cells in order to identify the main parameters of magnetic labeling and targeting systems. METHODS: Scientific data was searched in the PubMed, Cochrane Library, and eLIBRARY.RU databases for the period from January 2019 to September 2024 using the keywords magnetic cell targeting, magnetic cell delivery, magnetic cell localization, and magnetic cell guidance. Original experimental in vitro and in vivo studies were included if they involved labeling mammalian or human cells with magnetic nano- or microparticles for targeted delivery using magnetic fields. Data on study design, cell lines used, characteristics of magnetic particles, magnetic labeling conditions and efficiency, characteristics of magnetic trapping systems, efficiency of magnetic delivery, and clinical effects in in vivo disease models were extracted from the selected articles. RESULTS: A total of 62 articles were included in the analysis, of which 63% (39 studies) involved animal disease models, mainly affecting the nervous system, heart, eyes, urinary system, musculoskeletal system, and cancer. The most common labeled cells were multipotent mesenchymal stromal cells (27 studies), immune system cells (16 studies), and endothelial cells and their progenitors (7 studies). In most studies, superparamagnetic iron oxide nanoparticles were used for cell labeling (82% of studies) with more than 30 types of coatings, whereas neodymium magnets of various configurations at 0.005–1.450 T magnetic induction served as targeting systems. In 84% of studies, the optimal labeling concentration of magnetic particles ranged from 10–100 µg Fe/mL, with a labeling time of 4–24 h. A high degree of labeled cell magnetic controllability was demonstrated in vitro. In 19 animal studies, magnetic targeting resulted in a 1.16- to 20-fold increase in local cell concentration within the target area. In 85% of in vivo studies, magnetic targeting produced a more pronounced therapeutic effect compared with controls without targeting systems. Overall, the analysis confirms the high clinical potential of magnetic targeting in cell therapy. CONCLUSION: Magnetic targeting of cells using magnetic particles is a rapidly developing and promising technology in the field of regenerative medicine and cell therapy.
Zitieren
APA
Turchyn, V. V., Ishchenko, R. V., Bespalova, S. V., Solopov, M. V., Legenkiy, Y. A., Filimonov, D. A., & Popandopulo, A. G. (2026). Magnetic particles and targeting systems for magnetic cell delivery. Genes & Cells, 21(1), 62-76. https://doi.org/10.17816/gc690530
Vancouver
Turchyn VV, Ishchenko RV, Bespalova SV, Solopov MV, Legenkiy YA, Filimonov DA, et al. Magnetic particles and targeting systems for magnetic cell delivery. Genes & Cells. 2026;21(1):62-76. doi:10.17816/gc690530
BibTeX
@article{Turchyn2026,
author = {Turchyn, Viktor V. and Ishchenko, Roman V. and Bespalova, Svetlana V. and Solopov, Maksim V. and Legenkiy, Yuri A. and Filimonov, Dmitry A. and Popandopulo, Andrey G.},
title = {Magnetic particles and targeting systems for magnetic cell delivery},
journal = {Genes & Cells},
year = {2026},
volume = {21},
number = {1},
pages = {62--76},
doi = {10.17816/gc690530}
}
EUVIMED